Why Invest with Imagenetix

Below represents multiple reasons to invest in Imagenetix.

Imagenetix has an experienced management team with a proven track record in the public market and with natural-based products. Management is focused on creating value for shareholders by pursuing existing and well-defined multi-billion dollar markets. The companies non-pharmaceutical products compete in markets that are growing globally—these include skin care and nutritional supplements for weight management and joint pain/discomfort.
For select Imagenetix products that qualify for drug development, the Company seeks patent protection.
Celadrin®, the Company's lead, proprietary, natural-based product, is a scientifically tested product developed to provide support for healthy joint function and mobility. This creates an opportunity in a multi-billion dollar market for Imagenetix to generate significant sales as product recognition develops.
In its first few years of operations, Imagenetix has been diligent in creating product value, science, and channels of distribution from which to launch the Company and its products while at the same time remaining fiscally responsible.
The Company expects rapid growth as consumers become exposed to product information that will be forthcoming through scientific releases, conferences, papers, business and industry articles, celebrity endorsements, ads, media, and distributor marketing of the products.
The Company is in the early stages of conducting clinical trials and have completed two (2) university efficacy studies for its pharmaceutical compound (1-TDC) designed and developed to treat periodontal disease.
The company has received peer reviewed publication in its initial periodontal disease study - published in the May 2007 issue of the Journal of Periodontology (2007; 75: 924 – 932).